Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK.
about
Physical activity for lower urinary tract symptoms secondary to benign prostatic obstructionApoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic HyperplasiaTestosterone and benign prostatic hyperplasiaThe prevalence of benign prostatic hyperplasia in mainland China: evidence from epidemiological surveysCan we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.The study about physical activity for subjects with prevention of benign prostate hyperplasia.Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.Depression and Its Severity Are Strongly Associated with Both Storage and Voiding Lower Urinary Tract Symptoms Independently of Prostate Volume.Men's preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment.Understanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education (PROBE) II survey.The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis.Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia.24-month durability after crossover to the prostatic urethral lift from randomised, blinded sham.International Prostate Symptom Score Should Be Considered a Complement Rather Than a Substitute to Generic Preference-Based Measures for Measuring Lower Urinary Tract Symptoms Within Economic Evaluation.Flurbiprofen alone and in combination with alfuzosin for the management of lower urinary tract symptoms.Age Related Differences in Responsiveness to Sildenafil and Tamsulosin are due to Myogenic Smooth Muscle Tone in the Human Prostate.Positive Response to Thermobalancing Therapy Enabled by Therapeutic Device in Men with Non-Malignant Prostate Diseases: BPH and Chronic Prostatitis.Older Age and Larger Prostate Volume Are Associated with Stress Urinary Incontinence after Plasmakinetic Enucleation of the Prostate.Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model.Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia.Tailoring pharmacotherapy for male lower urinary tract symptoms: A prospective, multicenter, observational trial.Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement.Healthcare resource utilization and cost among males with lower urinary tract symptoms with a predominant storage component in Spain: The epidemiological, cross-sectional MERCURY study.Critical reviews of 1470-nm laser vaporization on benign prostatic hyperplasia.Economic Evaluation of Combination Therapy Versus Monotherapy for Treatment of Benign Prostatic Hyperplasia in Hong KongUrological dysfunctions in patients with Parkinson's disease: clues from clinical and non-invasive urological assessment
P2860
Q24186736-7A231C15-26F8-4D9A-A4C7-2A3C89147CCEQ26741226-D2AD1FFB-51EA-491A-9006-7C3988346978Q26863719-A0477DE6-13EF-46BF-B333-1175F50C38A8Q28082321-05DD271B-32BA-4703-93CF-BAB33AD66C5AQ31110115-66150707-D90D-4AB8-AD0C-7A37229FD022Q34267524-260985C2-1856-4F04-BFAB-C0983A4C9506Q35637347-49FF0D4E-4AD2-4072-9A5D-7B8F4A77F4F6Q36241740-0AA9859F-8322-434D-A151-0A2246725F0BQ37446463-91BFCC5A-5805-436D-AB49-0D111326387DQ37456507-02DA7617-612C-4D48-AC36-1B9A089E6452Q38628166-1A2556C1-D18E-4463-BD61-644111E170A1Q39163003-F40977D7-6902-439B-9C8E-4FCB8710343FQ39165097-6E2545B7-5A5F-4FFC-86CC-8A0631AD1289Q39561743-64B7C65E-5057-4E02-A093-603C9BD57D47Q39921832-7094DD2F-6561-40A0-ABF4-583DEA78CF7BQ41579675-E29DB854-DF0A-41F3-865F-68B773DFA2E8Q42023192-7CD9A3D7-12F5-4984-BA0B-C0A791A03AEAQ42363438-5ADA4249-DCB4-45B3-AEC3-AE5BEACD1B7FQ45339114-EEC908A5-1DA6-4D8F-8A81-750F71835A37Q47614558-D0DD0D24-406E-458A-A6F8-8DB728097D53Q48139585-C9E10BB5-5738-46AC-A9D3-F28AA1FDF78FQ48145224-2F078292-56D0-4B18-8B70-8D6167C403B3Q48206096-3EFB55C1-2941-45D6-BE29-4B2F7CDFA062Q48557445-E2215F64-92FC-4D86-88A3-1483907756A8Q58554211-A6EF1AE4-1681-4643-ACE6-877001445EBAQ58714123-BF92BCDB-8BFF-4D91-A3B0-D71B33107E0E
P2860
Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Burden of male lower urinary t ...... lasia (BPH) - focus on the UK.
@en
type
label
Burden of male lower urinary t ...... lasia (BPH) - focus on the UK.
@en
prefLabel
Burden of male lower urinary t ...... lasia (BPH) - focus on the UK.
@en
P2093
P2860
P356
P1433
P1476
Burden of male lower urinary t ...... lasia (BPH) - focus on the UK.
@en
P2093
Chris Ioannou
Mark Speakman
Roger Kirby
Scott Doyle
P2860
P304
P356
10.1111/BJU.12745
P577
2014-10-16T00:00:00Z